Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMYMP) Invested Capital (2016 - 2025)

Historic Invested Capital for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $63.3 billion.

  • Bristol Myers Squibb's Invested Capital fell 377.7% to $63.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $63.3 billion, marking a year-over-year decrease of 377.7%. This contributed to the annual value of $63.3 billion for FY2025, which is 377.7% down from last year.
  • Latest data reveals that Bristol Myers Squibb reported Invested Capital of $63.3 billion as of Q4 2025, which was down 377.7% from $67.3 billion recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year Invested Capital high stood at $88.7 billion for Q4 2021, and its period low was $63.3 billion during Q4 2025.
  • Over the past 5 years, Bristol Myers Squibb's median Invested Capital value was $69.2 billion (recorded in 2023), while the average stood at $73.3 billion.
  • Per our database at Business Quant, Bristol Myers Squibb's Invested Capital surged by 129.82% in 2023 and then plummeted by 2275.67% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Invested Capital stood at $88.7 billion in 2021, then fell by 5.2% to $84.1 billion in 2022, then increased by 1.3% to $85.2 billion in 2023, then dropped by 22.76% to $65.8 billion in 2024, then decreased by 3.78% to $63.3 billion in 2025.
  • Its last three reported values are $63.3 billion in Q4 2025, $67.3 billion for Q3 2025, and $66.4 billion during Q2 2025.